Popular on EntSun
- Disney Streamer Network Establishes Creator Code of Conduct - 386
- Commercial Manufacturing Validation Completed as November 10 FDA Milestone Approaches; Critical FDA Milestone Close: NRx Pharmaceuticals NAS DAQ: NRXP - 245
- Western Canadian Host James Cousineau Finishes 11th In Global "Top Host" Competition - 232
- Majo Aguilar inaugurates the Paseo de las Estrellas at Plaza Mexico with the unveiling of her Estrella Maya - 198
- Highsfield Showcases Earth Zoom Generator for Cinematic AI Videos - 190
- TÀBÍRA Studio Announces Permanent UK Entry and Upcoming London Showcase - 183
- Bacchus Wine & Spirits and Michelin Guide–Recommended Ethel's Fancy to Host Exclusive LOUIS XIII Limited Edition Diwali Decanter Celebration - 178
- The Return of Plaza México's 'Paseo de Las Estrellas' Honoring Recording Artist Majo Aguilar - 175
- OncoBeta Introduces Rhenium-SCT for Non-Melanoma Skin Cancer at Theageneio Cancer Hospital of Thessaloniki - 174
- Former Goddard Enterprises Managing Director Anthony Ali Joins STS Capital Partners as Managing Director and Partner - 173
Similar on EntSun
- Commercial Sales for U.S.-Made, Preservative-Free Ketamine Amid Long-Runnin Shortage Following FDA Approval by NRx Pharmaceuticals, Inc
- TCA VG: 2025 Funding Climbs to $9M across 43 Companies; Cumulative Returns Reach 5.3 MOIC & 22% IRR
- Commercial Sales Launch Following FDA Approval; National Sales Force Now in Action as January Shipments and Major Market Opportunity Take Shape
- OncoBeta Introduces Rhenium-SCT for Non-Melanoma Skin Cancer at Theageneio Cancer Hospital of Thessaloniki
- New Patient Data Show REQORSA® Activating Cellular Repair Pathways as Roche Collaboration Advances Precision Lung Cancer Strategy for Genprex, Inc
- New TROP2 Research Breakthrough Strengthens REQORSA® Gene Therapy Story as Roche Collaboration Advances Precision Lung Cancer Treatment: Genprex, Inc
- FDA Approval; Major Milestone for Preservative-Free Ketamine Ahead of FDA Goal Date for Treatment of Suicidal Depression by NRx Pharmaceuticals, Inc
- Major FDA Victory; Preservative-Free Ketamine Approved Ahead of November 10 Goal Date as Commercial Launch Opportunity Comes Into Focus for NRx Pharma
- New Research Spotlight, Expanding TUSC2 Science & Strategic Development Milestones Put Gene Therapy Innovation into Focus for Genprex (NAS DAQ: GNPX)
- Expanding Into Medically Supervised Wellness With Major Apollo Wellness Centers Announcement; Sibannac, Inc. (Stock Symbol: SNNC)
Preprint Reports Curtana's CT-179 Enhances Radiotherapy in an MGMT-Unmethylated Glioblastoma Model and Extends Survival as a Single Agent
EntSun News/11106229
Foundational preclinical study of the first-in-class, brain-penetrant OLIG2 inhibitor supports evaluating CT-179 with standard-of-care therapy, including in MGMT-unmethylated glioblastoma, where temozolomide adds little
AUSTIN, Texas - EntSun -- Curtana Pharmaceuticals, a clinical-stage biotechnology company focused on improving outcomes for brain cancer patients, today announced that a preprint posted on bioRxiv on October 20 reports that CT-179 extended survival as a single agent in two orthotopic patient-derived models of adult glioblastoma (GBM) and enhanced radiotherapy in an orthotopic MGMT-unmethylated model. CT-179 is a first-in-class, orally bioavailable, brain-penetrant small-molecule inhibitor of the transcription factor OLIG2. The study was led by Terrance G. Johns, Ph.D., and conducted at the Hudson Institute of Medical Research and Monash University, with collaborators at QIMR Berghofer, The University of Queensland, Mayo Clinic, Huntsman Cancer Institute at the University of Utah, and UT Southwestern Medical Center. The preprint has not yet been peer reviewed.
OLIG2 is expressed throughout diffuse gliomas, sustains the stem-like tumor cells that drive recurrence, and opposes p53-mediated responses to radiation and chemotherapy. Despite its established role in GBM, it has historically been considered undruggable.
Key findings reported in the preprint:
Cell death occurred while ERK1/2, AKT, and STAT3 survival signaling remained active, indicating that the effect is not explained by collapse of growth-factor receptor signaling. The authors also report greater-than-additive activity in vitro with Bcl-2 family inhibitors, which varied by cell line, identifying a further candidate combination strategy.
More on EntSun News
"OLIG2 has long been recognized as a central driver of glioblastoma, but it has resisted drug development," said Terrance G. Johns, Ph.D., corresponding author of the study. "This work shows that a small molecule can engage OLIG2 in patient-derived tumor cells, reach the brain, and add substantially to radiotherapy and temozolomide in our models."
"Seeing CT-179 deplete OLIG2-positive cells in patient-derived organoids and strengthen radiotherapy in an intracranial model gives us confidence in the translational rationale," said Bryan W. Day, Ph.D., Group Leader of the Sid Faithfull Brain Cancer Laboratory at QIMR Berghofer.
"The MGMT-unmethylated result is the most clinically relevant finding in this paper," said Gregory Stein, M.D., M.B.A., Chief Executive Officer of Curtana Pharmaceuticals. "These patients derive little benefit from temozolomide, and this data set directly informs the radiotherapy combination arm of our OPAL Phase 1 program. It adds to published reports from other laboratories of CT-179 activity in pediatric high-grade glioma and medulloblastoma, and in combination with immune checkpoint blockade."
About the Preprint
Greenall SA, Chen SC, et al. Pharmacologic inhibition of OLIG2 by CT-179 disrupts mitotic progression and enhances standard-of-care chemoradiotherapy in glioblastoma. bioRxiv. Posted October 20, 2026. doi: 10.64898/2026.10.14.759257. Available at https://www.biorxiv.org/content/10.64898/2026.10.14.759257v1. Preprints are preliminary reports that have not been peer reviewed and should not be regarded as conclusive.
About CT-179
CT-179 is a first-in-class, orally bioavailable, brain-penetrant small-molecule inhibitor of OLIG2, a master transcription factor in diffuse gliomas and OLIG2-positive medulloblastoma. CT-179 is designed to eliminate the cancer stem cells that drive recurrence, and published preclinical work shows that OLIG2 inhibition also relieves tumor-driven suppression of CXCL10 and sensitizes GBM to anti-PD-L1 therapy. The FDA has granted CT-179 Fast Track Designation, Orphan Drug Designation for gliomas, and Rare Pediatric Disease Designation for medulloblastoma and for pediatric high-grade glioma. Curtana's multi-site Phase 1 OPAL trial of CT-179 in glioblastoma will be conducted in Australia in partnership with the Cooperative Trials Group for Neuro-Oncology (COGNO).
More on EntSun News
About Curtana Pharmaceuticals
Curtana Pharmaceuticals, founded in 2013, is a privately held, clinical-stage biopharmaceutical company headquartered in Austin, Texas. Current investors include Thynk Capital, angelMD, Biosense Global, DEFTA Partners, the Musella Foundation, the Hasso Serrano Foundation, the Uncle Kory Foundation, and other anonymous investors. The company was also awarded a $7.6 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT). Curtana focuses on the development of novel, first-in-class small-molecule therapeutics targeting cancer stem cells in the central nervous system for the treatment of glioblastoma, low-grade glioma, medulloblastoma, diffuse midline glioma, and other brain cancers. For more information, visit https://www.curtanapharma.com/.
Forward-Looking Statements
This press release contains forward-looking statements regarding the preclinical and clinical development of CT-179, including the design and conduct of the multi-site Phase 1 OPAL study in glioblastoma and the potential of CT-179 in combination with radiotherapy and other agents. Results in preclinical models may not be predictive of results in patients. These forward-looking statements involve risks and uncertainties, including the outcome of peer review, the complexities of clinical trial execution and patient accrual, and the need to secure additional capital to fund operations and clinical milestones. Curtana undertakes no obligation to update these statements.
OLIG2 is expressed throughout diffuse gliomas, sustains the stem-like tumor cells that drive recurrence, and opposes p53-mediated responses to radiation and chemotherapy. Despite its established role in GBM, it has historically been considered undruggable.
Key findings reported in the preprint:
- Target engagement and activity across patient-derived lines. CT-179 bound OLIG2 in patient-derived GBM cells and altered the conformation of OLIG2 on DNA. It inhibited proliferation in all 11 patient-derived GBM cell lines tested (IC50 values below 360 nM), depleted the stem-like fraction, and induced apoptosis.
- Single-agent survival benefit in orthotopic models. Oral CT-179 crossed the blood-brain barrier and extended median survival in two independent orthotopic patient-derived xenograft models: by approximately 42% in GBM8 (P = 0.0139) and approximately 46% in MGMT-unmethylated G06 (43.0 vs. 29.5 days; P = 0.0034). Intraperitoneal dosing in GBM8 extended median survival from 46 to 70 days (P = 0.0052) and was associated with reduced intratumoral OLIG2 and Ki-67 staining.
- Combination with chemoradiotherapy. Added to radiotherapy and temozolomide, CT-179 eliminated all GBM8 and 7 of 8 GBM4 subcutaneous xenografts, both MGMT-methylated, with body weights comparable to controls.
- MGMT-unmethylated intracranial disease. In orthotopic MGMT-unmethylated GBM6 xenografts, where CT-179 alone did not significantly extend survival, adding intraperitoneal CT-179 to fractionated radiotherapy extended median survival compared with radiotherapy alone (48 vs. 38.5 days; P = 0.0248).
Cell death occurred while ERK1/2, AKT, and STAT3 survival signaling remained active, indicating that the effect is not explained by collapse of growth-factor receptor signaling. The authors also report greater-than-additive activity in vitro with Bcl-2 family inhibitors, which varied by cell line, identifying a further candidate combination strategy.
More on EntSun News
- Scoop Social Co. Brings Its Signature Mobile Dessert Experience to Minneapolis
- Holiday Events coming to the Weinberg Center and New Spire Arts this season
- LGF Lab Gas Flow Launches Fully Automatic Laboratory Gas Changeover Manifold System with Ultra High Purity Gas Regulator Valve
- From Startup to Successful Fashion Brand: How Laurent Gabay & Fashion Sourcing Help New Clothing Br
- Record Q3 Revenue and Gross Profit Delivered: Revenue Surges 40%, Gross Margin Soars to 36% & Adjusted EBITDA Loss Narrows 64% for Cycurion, Inc $CYCU
"OLIG2 has long been recognized as a central driver of glioblastoma, but it has resisted drug development," said Terrance G. Johns, Ph.D., corresponding author of the study. "This work shows that a small molecule can engage OLIG2 in patient-derived tumor cells, reach the brain, and add substantially to radiotherapy and temozolomide in our models."
"Seeing CT-179 deplete OLIG2-positive cells in patient-derived organoids and strengthen radiotherapy in an intracranial model gives us confidence in the translational rationale," said Bryan W. Day, Ph.D., Group Leader of the Sid Faithfull Brain Cancer Laboratory at QIMR Berghofer.
"The MGMT-unmethylated result is the most clinically relevant finding in this paper," said Gregory Stein, M.D., M.B.A., Chief Executive Officer of Curtana Pharmaceuticals. "These patients derive little benefit from temozolomide, and this data set directly informs the radiotherapy combination arm of our OPAL Phase 1 program. It adds to published reports from other laboratories of CT-179 activity in pediatric high-grade glioma and medulloblastoma, and in combination with immune checkpoint blockade."
About the Preprint
Greenall SA, Chen SC, et al. Pharmacologic inhibition of OLIG2 by CT-179 disrupts mitotic progression and enhances standard-of-care chemoradiotherapy in glioblastoma. bioRxiv. Posted October 20, 2026. doi: 10.64898/2026.10.14.759257. Available at https://www.biorxiv.org/content/10.64898/2026.10.14.759257v1. Preprints are preliminary reports that have not been peer reviewed and should not be regarded as conclusive.
About CT-179
CT-179 is a first-in-class, orally bioavailable, brain-penetrant small-molecule inhibitor of OLIG2, a master transcription factor in diffuse gliomas and OLIG2-positive medulloblastoma. CT-179 is designed to eliminate the cancer stem cells that drive recurrence, and published preclinical work shows that OLIG2 inhibition also relieves tumor-driven suppression of CXCL10 and sensitizes GBM to anti-PD-L1 therapy. The FDA has granted CT-179 Fast Track Designation, Orphan Drug Designation for gliomas, and Rare Pediatric Disease Designation for medulloblastoma and for pediatric high-grade glioma. Curtana's multi-site Phase 1 OPAL trial of CT-179 in glioblastoma will be conducted in Australia in partnership with the Cooperative Trials Group for Neuro-Oncology (COGNO).
More on EntSun News
- Inaugural 12 Trees of Christmas gala raises $525,000 for DMG research and family support
- BitTitan Expands MigrationWiz with SharePoint Sites Migration and Simplified Collaboration Licensing
- How Murder Mystery Games Work: The Technology Behind a Fully Automated Format
- BGE DD and Producer 9-0 Sets April 1, 2027 Release for The Royal Chamber
- Producer 9-0 Announces The Grand Salon and Salutes His Baroque Collaborators
About Curtana Pharmaceuticals
Curtana Pharmaceuticals, founded in 2013, is a privately held, clinical-stage biopharmaceutical company headquartered in Austin, Texas. Current investors include Thynk Capital, angelMD, Biosense Global, DEFTA Partners, the Musella Foundation, the Hasso Serrano Foundation, the Uncle Kory Foundation, and other anonymous investors. The company was also awarded a $7.6 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT). Curtana focuses on the development of novel, first-in-class small-molecule therapeutics targeting cancer stem cells in the central nervous system for the treatment of glioblastoma, low-grade glioma, medulloblastoma, diffuse midline glioma, and other brain cancers. For more information, visit https://www.curtanapharma.com/.
Forward-Looking Statements
This press release contains forward-looking statements regarding the preclinical and clinical development of CT-179, including the design and conduct of the multi-site Phase 1 OPAL study in glioblastoma and the potential of CT-179 in combination with radiotherapy and other agents. Results in preclinical models may not be predictive of results in patients. These forward-looking statements involve risks and uncertainties, including the outcome of peer review, the complexities of clinical trial execution and patient accrual, and the need to secure additional capital to fund operations and clinical milestones. Curtana undertakes no obligation to update these statements.
Source: Curtana Pharmaceuticals
0 Comments
Latest on EntSun News
- Producer 9-0 Credits Southern Miss and Ole Miss as Baroque Project Takes Shape
- Resident Evil's Wesker Is Now Beavis's "Bold New Voice" on Mike Judge's Beavis & Butt-Head
- Resident Evil's Wesker, D.C. Douglas, Plays the Villain in Texas Horror-Noir WHAT DID YOU DO?
- Hollywood Glam Night, December 30th, Marilyn Monroe Foundation & Anastasia Magazine
- Canadian Streamer CGP Spotlight Marks One Year With 1,000-Title Challenge
- Nine Platinum Honors Lead Scientology Media Productions' 12 Wins at 2026 MarCom Awards
- Entrepreneur Nouho M Kanneh Talks Family, Faith and a $37 Million Portfolio in New Interview
- The Creative Vision Behind Hollywood Music in Media Award-Nominated Mark Isham: The Voice Within
- Emerald Williams Selected to Super Lawyers Rising Stars 2022-2026
- El Show de Bernie: NJ Studio Launches Latino Animated Late-Night Talk Show Hosted by a Mexican Bear
- 98.FM Gospel Radio Realigns Airwaves: Prioritizing Scripture and New Artists Over Secular Metrics
- Entertainment Vet Latrina Blackberry Brings Upscale 40+ Experience "The Congo Den" to Spring, Texas
- Music For Good: Brooklyn's Legendary Gleason's Gym Transforms Into A Live Music Venue For One Night
- Massive Acquisition Into Defense With STS for Virtuix Holdings; $40 Million Revenue Business Will Accelerate Growth Transforming Market Position
- The Dining Room Sees Everything
- Orlando Real Estate Broker Bent Danholm Wins 2026 Goody Business Book Award for The Architecture of Demand
- Commercial Sales for U.S.-Made, Preservative-Free Ketamine Amid Long-Runnin Shortage Following FDA Approval by NRx Pharmaceuticals, Inc
- Independent Producer/Writer Karen Morris Announces The Swingin' Angle
- The King Returns: Satirical December 2026 Rematch Sees Challenger Delayed by a Christmas Light Installation
- Last Night of the Proms 2027 Tickets and Private Boxes on Sale at the Royal Albert Hall
